RxDoctor Payments Data

Scott Cooper, MD

Gastroenterology · Missoula, MTNPI 1821275900

Payments from drug & device makers

What this record shows

18 manufacturers reported payments, led by Covidien LP at 52.6% of the total. Reporting peaked in 2019 at $1,647 and has fallen 97.4% since, to $42 in 2025.

$2,784in general payments, 2019–2025

Across 40 payments — averaging $69.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Covidien LP$1K
  • Ambu Inc.$571
  • AbbVie$245
  • Apollo Endosurgery US Inc$145
  • Boston Scientific$50
  • Takeda Pharmaceuticals U.S.A., Inc.$44
  • plus $266 from 12 others
$78,584in research payments, 2019–2025

Across 20 payments — averaging $3929.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$79K

What the payments were for

  • Speaking & faculty fees$1,42451%
  • Food & beverage$1,36049%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,784 in reported general payments places this provider in the 85th percentile of 34 gastroenterology providers in Montana.

See all gastroenterology providers in Montana

Medicare billing

Part B allowed, 2024
$141,612
Medicare patients
542
Services billed
1,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase25$85,234
LinzessLinaclotide55$30,836
TrulancePlecanatide22$13,232
MovantikNaloxegol Oxalate19$7,798
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates84$5,151
Dexlansoprazole DrDexlansoprazole25$4,251
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg145$3,588
SutabSod Sulf/Pot Chloride/Mag Sulf13$1,993
Pantoprazole Sodium135$1,805
Budesonide DrBudesonide12$1,170
Omeprazole93$1,071
Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg41$838
Dicyclomine Hcl22$586
Famotidine49$542
Esomeprazole Magnesium24$353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$245$30,83655 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$36$13,23222 claims
Braintree Laboratories, Inc.Sutab$27$1,99313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 34 gastroenterology providers in Montana.

Other gastroenterology in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →